Diabetic Retinal Disease Redefined as a Whole-Retina Condition Demanding New Therapies
A landmark review reframes diabetic retinopathy as diabetic retinal disease, affecting neurons and glia—not just blood vessels—and outlines AI-driven and novel treatment advances.
Summary
A comprehensive 2025 review in Nature Reviews Disease Primers redefines diabetic retinopathy as diabetic retinal disease (DRD), recognizing that diabetes damages the entire retina—including neurons and glial cells—not merely the microvasculature. The review synthesizes current evidence from major clinical trials, highlights progress in personalized screening using artificial intelligence, and evaluates emerging therapies aimed at improving durability, affordability, and vision-related quality of life. Authors from leading global institutions underscore the urgency of integrated, systemic approaches to reduce the worldwide burden of diabetes-related blindness.
Detailed Summary
Diabetic eye disease remains one of the leading causes of preventable blindness globally, affecting hundreds of millions of people with diabetes mellitus. This 2025 primer in Nature Reviews Disease Primers represents a significant conceptual and clinical update, calling for a shift in terminology from diabetic retinopathy to diabetic retinal disease (DRD) to better reflect the full scope of retinal pathology involved.
The authors argue that the classical view—focusing primarily on microvascular changes such as microaneurysms and neovascularization—is insufficient. Diabetes also damages retinal neurons and glial cells, meaning that structural and functional changes occur across the entire retina. This broader understanding reshapes how the disease should be studied, diagnosed, and treated.
Drawing on robust evidence from the Diabetic Retinopathy Clinical Research Retina Network (DRCR Retina Network) and other major research efforts, the review covers current standard-of-care management for vision-threatening manifestations including proliferative diabetic retinopathy and diabetic macular edema. Anti-VEGF therapies and laser treatments remain cornerstones, but the field is rapidly evolving.
A major focus is the integration of artificial intelligence as a clinical decision-support tool for cost-effective, personalized screening and monitoring—particularly critical in lower-resource settings where ophthalmologist access is limited. Novel therapeutic agents and delivery mechanisms are also under evaluation, with goals of extending treatment durability and reducing patient burden.
The review acknowledges that this is a primer based on existing literature rather than original trial data, which limits the novelty of specific findings. Additionally, several authors disclose extensive industry relationships, which warrants consideration when interpreting emphasis areas. Nonetheless, this synthesis provides a vital framework for clinicians and researchers navigating the rapidly expanding DRD landscape.
Key Findings
- Diabetic retinopathy is now better termed diabetic retinal disease (DRD), as neurons and glia are also affected.
- DRCR Retina Network trials provide robust evidence supporting current management of proliferative DR and diabetic macular edema.
- AI-powered tools are advancing personalized, cost-effective screening and clinical decision support for DRD.
- Novel therapies and delivery systems are being evaluated to improve treatment durability and global affordability.
- Integrating systemic health and biochemical data with retinal findings is a key emerging research direction.
Methodology
This is a comprehensive narrative review primer published in Nature Reviews Disease Primers, synthesizing preclinical and clinical evidence from major trials and global research initiatives. It is not a meta-analysis or original clinical trial. The review integrates findings on pathophysiology, epidemiology, clinical management, and emerging technologies.
Study Limitations
This is a review article without original data, limiting the strength of any new clinical conclusions. Multiple authors report significant conflicts of interest with pharmaceutical and device companies, which may influence the framing of treatment evidence. Access to the full text was unavailable; this summary is based solely on the abstract.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.